CAM
ALNY icon

ClariVest Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

ClariVest Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$1K – 874
2023
Q3 		$1K Hold
4
– – ﹤0.01% 557
2023
Q2 		$1K Hold
4
– – ﹤0.01% 572
2023
Q1 		$1K Hold
4
– – ﹤0.01% 605
2022
Q4 		$1K Hold
4
– – ﹤0.01% 583
2022
Q3 		$1K Hold
4
– – ﹤0.01% 566
2022
Q2 		$1K Hold
4
– – ﹤0.01% 577
2022
Q1 		$1K Hold
4
– – ﹤0.01% 613
2021
Q4 		$1K Hold
4
– – ﹤0.01% 662
2021
Q3 		$1K Hold
4
– – ﹤0.01% 659
2021
Q2 		$1K Hold
4
– – ﹤0.01% 651
2021
Q1 		$1K Hold
4
– – ﹤0.01% 629
2020
Q4 		$1K Hold
4
– – ﹤0.01% 649
2020
Q3 		$1K Hold
4
– – ﹤0.01% 641
2020
Q2 		$1K Sell
4
-16,696
-100% -$2.25M ﹤0.01% 708
2020
Q1 		$1.82M Buy
16,700
+1,300
+8% +$150K 0.05% 208
2019
Q4 		$1.77M Sell
15,400
-500
-3% -$49.8K 0.04% 263
2019
Q3 		$1.28M Sell
15,900
-200
-1% -$15.8K 0.03% 317
2019
Q2 		$1.17M Sell
16,100
-100
-0.6% -$7.67K 0.03% 296
2019
Q1 		$1.51M Sell
16,200
-400
-2% -$33.5K 0.03% 352
2018
Q4 		$1.21M Hold
16,600
– – 0.03% 370
2018
Q3 		$1.45M Hold
16,600
– – 0.03% 371
2018
Q2 		$1.64M Sell
16,600
-2,900
-15% -$288K 0.03% 371
2018
Q1 		$2.32M Hold
19,500
– – 0.04% 319
2017
Q4 		$2.48M Buy
+19,500
New +$2.45M 0.04% 313
2015
Q2 		– Sell
-6,734
Closed -$703K – 603
2015
Q1 		$703K Sell
6,734
-94
-1% -$9.53K 0.02% 318
2014
Q4 		$662K Sell
6,828
-13
-0.2% -$1.2K 0.02% 261
2014
Q3 		$535K Sell
6,841
-6
-0.1% -$387 0.02% 267
2014
Q2 		$432K Buy
6,847
+9
+0.1% +$535 0.02% 286
2014
Q1 		$459K Buy
+6,838
New +$529K 0.02% 273

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ClariVest Asset Management's ALNY Position: Q4 2023 in Review

ClariVest Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 4 shares — an estimated $1K sold.

ClariVest Asset Management first reported a position in ALNY in Q1 2014 and held it in 29 quarters. The position peaked at $2.48M in Q4 2017. 499 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • ClariVest Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • ClariVest Asset Management sold 4 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $1K.
  • ClariVest Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2014 and held it in 29 quarters.
  • ClariVest Asset Management's Alnylam Pharmaceuticals position peaked at $2.48M in Q4 2017.
  • 499 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on ClariVest Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.